Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience

D. O. Dixon, B. Neilan, S. E. Jones, D. A. Lipschitz, Thomas P Miller, P. N. Grozea, H. E. Wilson

Research output: Contribution to journalArticle

314 Citations (Scopus)

Abstract

To study the influence of chronologic age on treatment outcome in patients with advanced, diffuse large-cell (histiocytic) lymphoma (DHL), we reviewed the results of two recent Southwest Oncology Group (SWOG) clinical trials. From 1974 to 1982, members entered 307 eligible patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without bleomycin, and CHOP with or without immunotherapy using BCG, levamisole, or both. Complete response (CR) rates declined progressively with advancing age: 65% in those under 40, 60% in the 40 to 54 age group, 55% in the 55 to 64 age group, and 37% in those 65 and older (P = .001). Likewise, survival decreased significantly in older patients: medians were 101+, 52, 34, and 16 months, respectively (P < .001). Treatment guidelines included an initial dose reduction of 50% for patients aged 65 or older and for younger patients with bone marrow compromise. Despite protocol specifications, 23 of 81 patients aged 65 or older received initial full-dose therapy. When these patients were compared with younger patients on whom full-dose chemotherapy was started, survival curves, but not CR rates, were still significantly different. There were no significant differences in duration of CR or frequency of treatment complications. These data suggest that older age is associated with a worse prognosis in advanced DHL. Moreover, the initial dose reduction for patients aged 65 or older may have contributed to their inferior outcomes.

Original languageEnglish (US)
Pages (from-to)295-305
Number of pages11
JournalJournal of Clinical Oncology
Volume4
Issue number3
StatePublished - 1986
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Therapeutics
Age Groups
Levamisole
Survival
Bleomycin
Vincristine
Mycobacterium bovis
Prednisone
Immunotherapy
Doxorubicin
Cyclophosphamide
Bone Marrow
Clinical Trials
Guidelines
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dixon, D. O., Neilan, B., Jones, S. E., Lipschitz, D. A., Miller, T. P., Grozea, P. N., & Wilson, H. E. (1986). Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. Journal of Clinical Oncology, 4(3), 295-305.

Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma : The Southwest Oncology Group experience. / Dixon, D. O.; Neilan, B.; Jones, S. E.; Lipschitz, D. A.; Miller, Thomas P; Grozea, P. N.; Wilson, H. E.

In: Journal of Clinical Oncology, Vol. 4, No. 3, 1986, p. 295-305.

Research output: Contribution to journalArticle

Dixon, DO, Neilan, B, Jones, SE, Lipschitz, DA, Miller, TP, Grozea, PN & Wilson, HE 1986, 'Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience', Journal of Clinical Oncology, vol. 4, no. 3, pp. 295-305.
Dixon, D. O. ; Neilan, B. ; Jones, S. E. ; Lipschitz, D. A. ; Miller, Thomas P ; Grozea, P. N. ; Wilson, H. E. / Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma : The Southwest Oncology Group experience. In: Journal of Clinical Oncology. 1986 ; Vol. 4, No. 3. pp. 295-305.
@article{e556c9452b924e64ad4ff5c85aee3864,
title = "Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience",
abstract = "To study the influence of chronologic age on treatment outcome in patients with advanced, diffuse large-cell (histiocytic) lymphoma (DHL), we reviewed the results of two recent Southwest Oncology Group (SWOG) clinical trials. From 1974 to 1982, members entered 307 eligible patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without bleomycin, and CHOP with or without immunotherapy using BCG, levamisole, or both. Complete response (CR) rates declined progressively with advancing age: 65{\%} in those under 40, 60{\%} in the 40 to 54 age group, 55{\%} in the 55 to 64 age group, and 37{\%} in those 65 and older (P = .001). Likewise, survival decreased significantly in older patients: medians were 101+, 52, 34, and 16 months, respectively (P < .001). Treatment guidelines included an initial dose reduction of 50{\%} for patients aged 65 or older and for younger patients with bone marrow compromise. Despite protocol specifications, 23 of 81 patients aged 65 or older received initial full-dose therapy. When these patients were compared with younger patients on whom full-dose chemotherapy was started, survival curves, but not CR rates, were still significantly different. There were no significant differences in duration of CR or frequency of treatment complications. These data suggest that older age is associated with a worse prognosis in advanced DHL. Moreover, the initial dose reduction for patients aged 65 or older may have contributed to their inferior outcomes.",
author = "Dixon, {D. O.} and B. Neilan and Jones, {S. E.} and Lipschitz, {D. A.} and Miller, {Thomas P} and Grozea, {P. N.} and Wilson, {H. E.}",
year = "1986",
language = "English (US)",
volume = "4",
pages = "295--305",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma

T2 - The Southwest Oncology Group experience

AU - Dixon, D. O.

AU - Neilan, B.

AU - Jones, S. E.

AU - Lipschitz, D. A.

AU - Miller, Thomas P

AU - Grozea, P. N.

AU - Wilson, H. E.

PY - 1986

Y1 - 1986

N2 - To study the influence of chronologic age on treatment outcome in patients with advanced, diffuse large-cell (histiocytic) lymphoma (DHL), we reviewed the results of two recent Southwest Oncology Group (SWOG) clinical trials. From 1974 to 1982, members entered 307 eligible patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without bleomycin, and CHOP with or without immunotherapy using BCG, levamisole, or both. Complete response (CR) rates declined progressively with advancing age: 65% in those under 40, 60% in the 40 to 54 age group, 55% in the 55 to 64 age group, and 37% in those 65 and older (P = .001). Likewise, survival decreased significantly in older patients: medians were 101+, 52, 34, and 16 months, respectively (P < .001). Treatment guidelines included an initial dose reduction of 50% for patients aged 65 or older and for younger patients with bone marrow compromise. Despite protocol specifications, 23 of 81 patients aged 65 or older received initial full-dose therapy. When these patients were compared with younger patients on whom full-dose chemotherapy was started, survival curves, but not CR rates, were still significantly different. There were no significant differences in duration of CR or frequency of treatment complications. These data suggest that older age is associated with a worse prognosis in advanced DHL. Moreover, the initial dose reduction for patients aged 65 or older may have contributed to their inferior outcomes.

AB - To study the influence of chronologic age on treatment outcome in patients with advanced, diffuse large-cell (histiocytic) lymphoma (DHL), we reviewed the results of two recent Southwest Oncology Group (SWOG) clinical trials. From 1974 to 1982, members entered 307 eligible patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without bleomycin, and CHOP with or without immunotherapy using BCG, levamisole, or both. Complete response (CR) rates declined progressively with advancing age: 65% in those under 40, 60% in the 40 to 54 age group, 55% in the 55 to 64 age group, and 37% in those 65 and older (P = .001). Likewise, survival decreased significantly in older patients: medians were 101+, 52, 34, and 16 months, respectively (P < .001). Treatment guidelines included an initial dose reduction of 50% for patients aged 65 or older and for younger patients with bone marrow compromise. Despite protocol specifications, 23 of 81 patients aged 65 or older received initial full-dose therapy. When these patients were compared with younger patients on whom full-dose chemotherapy was started, survival curves, but not CR rates, were still significantly different. There were no significant differences in duration of CR or frequency of treatment complications. These data suggest that older age is associated with a worse prognosis in advanced DHL. Moreover, the initial dose reduction for patients aged 65 or older may have contributed to their inferior outcomes.

UR - http://www.scopus.com/inward/record.url?scp=0022602852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022602852&partnerID=8YFLogxK

M3 - Article

C2 - 3512783

AN - SCOPUS:0022602852

VL - 4

SP - 295

EP - 305

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -